Saperconazole therapy in a rabbit model of invasive aspergillosis.
The efficacy of orally and intravenously administered saperconazole against Aspergillus fumigatus was assessed in an immunosuppressed temporarily leukopenic rabbit model of invasive aspergillosis and compared with that of amphotericin B. Oral saperconazole at dosages of 5, 10, and 15 mg/kg of body weight per day improved survival compared with that of controls. In addition, saperconazole at 10 and 15 mg/kg/day reduced the tissue burden and reduced levels of circulating antigen, which correlated with increasing dosages of saperconazole. Intravenous saperconazole produced levels in serum more than 10-fold that of oral therapy. Intravenous saperconazole not only improved survival and reduced antigen levels but also significantly eradicated A. fumigatus from tissues compared with those of controls and was as effective as amphotericin B in these studies. Saperconazole was effective in the treatment of experimental invasive aspergillosis and demonstrates the potential of the newer azoles in therapy for invasive aspergillosis.
Patterson
T F
TF
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510.
George
D
D
Miniter
P
P
Andriole
V T
VT
D000284:Administration, Oral; D000666:Amphotericin B / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D001232:Aspergillus fumigatus; D001393:Azoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D007275:Injections, Intravenous; D008826:Microbial Sensitivity Tests; D011817:Rabbits
D000935:Antifungal Agents; D001393:Azoles; D000666:Amphotericin B; C060571:saperconazole